Pricing Log in Create free account

Intellia Therapeutics, Inc. (NTLA) vs SELLAS Life Sciences Group, Inc. (SLS)

Intellia Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($1.6B and $1.6B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −805.8%) and the higher return on invested capital (0.00% vs −195.3%). Across the 15 metrics below, SELLAS Life Sciences Group, Inc. leads on 10 and Intellia Therapeutics, Inc. on 5.

Valuation

Metric NTLA SLS Biotechnology median
P/E n/m n/m 10.60
P/S 29.87 149.37 9.40
P/B 2.58 11.39 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 20.91 136.22 9.02
Earnings yield (29.72%) (2.53%) (32.88%)
Free cash flow yield (22.60%) (2.45%) (23.13%)

Profitability

Metric NTLA SLS Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (821.24%) 0.00% 0.00%
Net margin (805.75%) 0.00% 0.00%
Free cash flow margin (671.57%) 0.00% 0.00%
Return on equity (62.60%) (39.63%) (51.96%)
Return on assets (46.63%) (36.54%) (46.06%)
Return on invested capital (195.32%) 0.00% 0.00%

Growth

Metric NTLA SLS Biotechnology median
Revenue growth (TTM) (8.07%) — 6.76%
EPS growth (last fiscal year) 27.43% 50.00% 29.88%
Revenue growth, 5-year CAGR 3.13% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NTLA SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.31 18.83 4.97
Net debt to EBITDA 1.06 2.54 1.01

Dividend

Metric NTLA SLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NTLA SLS Biotechnology median
Market cap 1.56b 1.59b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack